Oxford BioDynamics (LON:OBD) Trading Up 0.5% – Still a Buy?

Shares of Oxford BioDynamics Plc (LON:OBD) shot up 0.5% during trading on Monday . The company traded as high as GBX 0.40 ($0.01) and last traded at GBX 0.38 ($0.00). 13,090,715 shares changed hands during trading, a decline of 29% from the average session volume of 18,447,652 shares. The stock had previously closed at GBX 0.37 ($0.00).

Analyst Ratings Changes

Separately, Shore Capital reissued a “house stock” rating on shares of Oxford BioDynamics in a research note on Thursday, March 13th.

Oxford BioDynamics Stock Up 0.5%

The stock has a 50 day moving average price of GBX 0.44 and a 200 day moving average price of GBX 0.77. The stock has a market capitalization of £7.07 million, a price-to-earnings ratio of -0.07 and a beta of 0.42. The company has a quick ratio of 2.80, a current ratio of 0.68 and a debt-to-equity ratio of 370.22.

Oxford BioDynamics (LON:OBD) last announced its quarterly earnings results on Friday, February 28th. The biotechnology company reported GBX (4.50) (($0.06)) EPS for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.